Propensity Score Matching Analysis for Alcohol‐Related Liver Disease

Propensity Score Matching Analysis for Alcohol‐Related Liver Disease

ABSTRACT Objectives This study aims to investigate the impact of comorbidity with chronic hepatitis B (CHB) on the survival rates and incidence of liver cancer in patients with alcohol‐related liver disease (ARLD). Methods Patients with ARLD and those with ARLD co‐morbid with CHB were included in th...

Full description

Saved in:
Bibliographic Details
Main Authors: Fangfang Duan, Shanshan Song, Hang Zhai, Yazhi Wang, Jun Cheng, Song Yang
Format: Article
Language:English
Published: Wiley 2025-01-01
Series:Health Science Reports
Subjects:
alcohol‐related liver disease
chronic hepatitis B
liver‐specific mortality
propensity scoring matching
Online Access:https://doi.org/10.1002/hsr2.70257
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:ABSTRACT Objectives This study aims to investigate the impact of comorbidity with chronic hepatitis B (CHB) on the survival rates and incidence of liver cancer in patients with alcohol‐related liver disease (ARLD). Methods Patients with ARLD and those with ARLD co‐morbid with CHB were included in this study and designated as the ARLD group and the ARLD + HBV group, respectively. Propensity score matching (PSM) was then employed to compare survival rates and liver cancer development between these two groups. Results Among the 404 patients, 254 were in the ARLD group and 150 in the ARLD + HBV group. After propensity score matching, each group comprised 67 patients. Initially, the ARLD + HBV group exhibited lower 5‐year survival rates compared to the ARLD group (51.3% vs. 70.1%, p < 0.001). However, PSM mitigated this difference, with survival rates now comparable (61.2% vs. 60.9%, p = 0.390). Notably, the ARLD + HBV group showed a higher incidence of liver‐specific mortality after matching (32.6% vs. 6.2%, p = 0.018). Furthermore, although a higher proportion of patients in the ARLD + HBV group developed liver cancer post‐matching, the difference was not statistically significant compared to the ARLD group (15.7% vs. 9.8%, p = 0.170). Conclusion Co‐morbidity with CHB in ARLD patients elevates the risk of liver‐related mortality.
ISSN:2398-8835

Similar Items